Human antibodies specific for glycoprotein C (gC1) of herpes simplex virus type 1 (HSV-1) neutralized the virus infectivity and efficiently inhibited attachment of HSV-1 to human HaCaT keratinocytes and to murine mutant L cells expressing either heparan sulfate or chondroitin sulfate at the cell surface. Similar activities were observed with anti-gC1 monoclonal antibody B1C1. In addition to HaCaT and L cells, B1C1 antibody neutralized HSV-1 infectivity in simian GMK AH1 cells mildly pre-treated with heparinase III. Human anti-gC1 antibodies efficiently competed with the binding of gC1 to B1C1 antibody whose epitope overlaps a part of the attachment domain of gC1. Human anti-gC1 and B1C1 antibodies extended survival time of mice experimentally infected with HSV-1. We conclude that in HaCaT cells and in cell systems showing restricted expression of glycosaminoglycans, human and some monoclonal anti-gC1 antibodies can target the cellbinding domain of this protein and neutralize viral infectivity.
Introduction
Herpes simplex virus type 1 (HSV-1) can maintain a life-long, persistent infection and cause recurrent mucocutaneous lesions despite a vigorous immune response to viral components including envelope glycoproteins. A prevailing rationale for attempts to develop HSV vaccine has been to amplify such an immune response against selected envelope glycoproteins (e.g. glycoproteins B and D) that induce virus-neutralizing antibodies. Despite promising results in animal models, the vaccine constructs based on this concept conferred limited and short-lasting protection in humans (Corey et al., 1999) . It is therefore of interest to characterize the human immune response to other viral components such as HSV-1 glycoprotein C (gC) that were not included in the tested vaccine.
Glycoprotein C (gC1) of HSV-1 is regarded as the major virus attachment component that mediates binding of the virus to cell surface heparan sulfate (HS) (Herold et al., 1991; Svennerholm et al., 1991; Tal-Singer et al., 1995; Trybala et al., 1994; WuDunn and Spear, 1989) or chondroitin sulfate (CS), the latter functioning as an auxiliary receptor for the gC1-mediated binding activity in the absence of HS chains Mardberg et al., 2002) . It should be emphasized that because gC1 is non-essential for HSV-1 replication in cultured cells another viral protein can also mediate attachment of HSV-1 to cells. Griffiths et al. (1998) reported that the gC1-deficient mutants of two HSV-1 strains were not impaired in their binding to Vero cells, and further data from the same laboratory (Babic et al., 1999) revealed that gC1-deficient viruses infected cultured mammalian neurons with fiveto tenfold reduced efficiency relative to wildtype gC1-proficient HSV-1. Altogether, available data suggest that the extent of gC1 involvement in the binding of HSV-1 to cultured cells is both virus strain and cell type dependent (reviewed by Spear, 2004) . Although non-essential for virus replication in cultured cells, this glycoprotein seems to provide an important function for viral infection in humans as probing of almost five thousand HSV-1 isolates for the presence of gC1 failed to identify a gC1-deficient variant (Liljeqvist et al., 1999) .
In contrast to what has been reported for several animal alphaherpesviruses such as pseudorabies virus (Ober et al., 2000) , it is not known whether natural host antibodies to HSV-1 gC1 could neutralize the virus infectivity in cultured cells. Clarification of this issue is complicated by the fact that during HSV-1 infection of most cell lines, another glycoprotein, i.e. gB, may provide an alternate attachment function (Herold et al., 1994) . In search for limiting cell culture systems for studies of gC1 functions, we have demonstrated a gC1-dependency of the HSV-1 binding to mutant mouse L cells that exhibit selective defect in glycosaminoglycan (GAG) expression (Mardberg et al., 2002) . Thus, we reasoned that such cell systems could be utilized for functional studies of the human antibody response to gC1.
By using scanning mutagenesis, monoclonal antibody (MAb)resistant mutants and peptides specific for gC1, we have previously identified a major HS-binding domain of HSV-1 gC at the N-terminal part of the protein, comprising aa residues 129-RR-130 and 142-IRCRFRNSTRMEFRLQIWR-160 as well as another region around G247 (Trybala et al., 1994 , Mardberg et al., 2001 . In addition, the mucinlike region of gC1 delimited by aa P33 and G123 was also proposed to play a vital role in HS-binding activity (Tal-Singer et al., 1995) . Later studies from our group showed that a somewhat enlarged domain of gC1, encompassing also the residues K114, R117, K120, and I142 conveyed the virus binding to CS, and identified CS type E units as an important part of the glycan receptor structure (Mardberg et al., 2002; Bergefall et al., 2005) . Interestingly, an epitope of the anti-gC MAb B1C1 that is well conserved among clinical HSV-1 isolates may overlap the GAG-binding domain of this protein (Trybala et al., 1994 , Liljeqvist et al., 1999 Olofsson et al., 1999; Mardberg et al., 2001) . Previous mapping of this epitope has shown that MAb B1C1 interacted with gC residues R143, R145, T150 and G 247 (Trybala et al., 1994; Mardberg et al., 2001; Olofsson et al., 1999) . Despite this, the MAb was previously found to weakly neutralize infectivity of HSV-1 in cultures of green monkey kidney AH1 cells (GMK AH1) (Svennerholm et al., 1991) . In the present report we found that human anti-gC1 antibody and MAb B1C1 neutralized HSV-1 infectivity in human keratinocyte HaCaT cells, and in mutant L cells expressing HS or CS as sole cell surface GAGs. Similar activity of MAb B1C1 was also observed in GMK AH1 cells that had been mildly pre-treated with a HSdegrading enzyme. Furthermore, human anti-gC antibodies blocked the binding of the MAb B1C1 to gC, indicating that the human B-cell response successfully targets the major GAG attachment site of HSV-1 gC. Finally, the experiment estimating the in vivo protective capacity of anti-gC1 antibodies showed that these antibodies extended survival time of mice experimentally infected with HSV-1.
Results

Anti-gC antibodies inhibit HSV-1 infection to HaCaT keratinocytes and to cells expressing restricted GAG types
To investigate the virus-neutralizing activity of human antibodies specific for gC of HSV-1, we tested the effect of purified human anti-gC1 antibodies on HSV-1 infection of murine L, sog9-EXT1, and gro2C cells. Human HaCaT cells, i.e. cell line derived from keratinocytes which are known to be targeted during HSV-1 infection of humans, and simian GMK AH1 cells were also used in this experiment. Anti-gC1 antibodies were purified from sera of three HSV-1 isolationpositive patients by the gC1-affinity chromatography while sera from patients infected with HSV-2 only and sera from seronegative subjects (for description of sera, see Table 1 ) were used as controls. Preincubation of HSV-1 for 30 min at 37°C with purified anti-gC1 antibodies, but not with HSV-2 positive or HSV-negative sera, efficiently neutralized HSV-1 infectivity in CS-expressing gro2C ( Fig. 1B) and HSexpressing sog9-EXT1 (Fig. 1C ) cells. In the parental L cells, the virusneutralizing capability of anti-gC1 antibodies was slightly reduced as compared to that observed in gro2C and sog9-EXT1 cells (Fig. 1A) . Anti-gC1 antibodies also neutralized HSV-1 infectivity in HaCaT keratinocytes ( Fig. 1D ) but not in GMK AH1 cells ( Fig. 1E ). Somewhat more efficient neutralization of HSV-1 infectivity by human anti-gC1 antibodies in gro2C and sog9-EXT1 than in L cells could be related to the expression of restricted categories of GAG molecules, and to the fact that unlike L cell sog9-EXT1 produce lesser quantities and relatively undersulfated chains of HS (McCormick et al., 1998) . Possible extension of this conclusion to L or HaCaT cells would require comparative analysis of GAGs expressed in these cells and in GMK AH1 cells including the amount of GAG produced, chain length and sulfation pattern.
We also tested the HSV-1 neutralizing activity of murine anti-gC1 monoclonal antibodies (MAbs) B1C1 and C2H12. These MAbs were tested under experimental conditions similar to these used for human anti-gC antibodies. MAb B1C1 ( Fig. 2A ) but not C2H12 ( Fig. 2B ) neutralized HSV-1 infectivity in gro2C, sog9-EXT1, and to lesser extent in L cells. B1C1 also exhibited the virus-neutralizing activity in HaCaT but not in GMK AH1 cells. These results indicate that MAb B1C1 and human anti-gC1 antibodies show similar pattern of neutralization of HSV-1 infectivity in mutant murine L cells and in HaCaT cells.
Since the here demonstrated neutralization activity was most clearly shown in mutant cell types with reduced GAG expression, we then wanted to address the question whether a reduction of the amount of GAGs on the surface of GMK AH1 cells would render MAb B1C1 a neutralizing capacity also on this cell type. To this end, GMK AH1 cells were treated with relatively low concentration (1 U/ml) of the endoglycosidases heparinase I, heparinase III and chondroitinase ABC. At this concentration these enzymes reduced weakly or not at all the HSV-1 infectivity (Fig. 3) . Interestingly, the infectivity of HSV-1 was efficiently blocked by MAb B1C1 (but not by C2H12) only on cells pre-treated with heparinase III (Fig. 3 ), the enzyme that specifically cleaves HS linkages at regions with reduced density of chain sulfation.
Anti-gC antibodies reduce HSV-1 attachment to HaCaT keratinocytes and to cells expressing restricted GAG types
To investigate whether the virus-neutralizing activity of human anti-gC1 antibodies was due to interference with the virus binding to cells, antibodies purified from several human sera were pooled and tested for their capability to inhibit attachment of purified radiolabeled HSV-1 virions to cells. The most efficient reduction of HSV-1 binding by anti-gC1 antibodies was observed in gro2C cells, then followed sog9-EXT1, HaCaT and L cells, and GMK AH1 cells ( Fig. 4A ). Note that this hierarchy was similar to that found with the anti-gC1 antibodies in the virus neutralization assay (Fig. 1) .
To further clarify whether anti-gC1 antibodies can neutralize the virus by interfering with attachment functions of this protein, we also tested the effects of anti-gC1 MAbs B1C1 and C2H12 on binding of HSV-1 to cells. B1C1 antibody reduced the virus binding to sog9-EXT1 and gro2C cells substantially (Fig. 4B ). Less pronounced reduction in HSV-1 binding was observed in HaCaT and L cells but not in GMK AH1 cells. In contrast C2H12 antibody affected the virus binding to sog9-EXT1 cells modestly, and exhibited no inhibitory effects in other cells ( Fig. 4C ). Note that in the concentration range of 1 to 10 µg/ml, the human anti-gC1 antibodies were as efficient in inhibiting the virus attachment to cells as was the MAb B1C1 (see Figs. 4A and B ). The 
a Serum samples were investigated for presence of IgM antibodies to HSV by immunofluorescence. HSV IgG antibodies were tested by ELISA using a type-common HSV antigen (HSG), HSV-1 gG (gG1), HSV-1 gC (gC1), and HSV-2 gG (gG2). b n.d.: not done. more efficient inhibition by MAb B1C1 of HSV-1 infectivity ( Fig. 2A ) than the virus binding activity (Fig. 4B) is likely due to the relatively high quantity of virus used in the attachment assay as the radioactivity of virus preparations (PFU/cpm) used were ∼ 100. Because B1C1 MAb and human anti-gC1 antibodies showed similar inhibitory effects in the virus neutralization (Figs. 1 and 2) and the virus attachment assays (Fig. 4) , we sought to determine whether the B1C1 epitope overlaps the attachment domain of gC1. To identify an epitope for the B1C1 antibody, eight different baculovirus-expressed gC1 constructs were used. Structural details of these recombinant proteins are schematically outlined in Table 2 . In comparison with the native gC, these fragments contain terminal and/or internal deletions of long stretches of amino acids. Table 2 also includes a panel of eight site-altered HSV-1 mutants in gC1 prepared by alanine/threonine/ isoleucine substitution for specific amino acid (aa) residues of gC1. In an ELISA assay, all baculovirus-expressed gC1 fragments including the smallest one (aa 82-209; gGC1-ΔssΔ210) were recognized by MAb C2H12 (Table 2) . Because C2H12 bound to the gC1 fragment carrying deletion of aa 33-123 (C1-ΔmucTM − H), an epitope for this antibody seemed to be localized in a gC1 region delimited by aa 124-209. Indeed, pepscan analysis revealed that the predicted epitope for this antibody was delimited by aa 201 PHVLW 205 (data not shown). Note that this epitope for C2H12 antibody is located outside the gC1 attachment domain (Mardberg et al., 2001 (Mardberg et al., , 2002 thus explaining lack of activity of C2H12 in the virus neutralization and attachment assays (Figs. 2 and 4). B1C1 MAb showed no reactivity with gC1 constructs Fig. 1 . Neutralization of the HSV-1 infectivity by purified human anti-gC1 antibodies in cultured cells. The virus was incubated at 37°C for 30 min with serial twofold dilutions of either anti-gC1 antibodies purified from three HSV-1 positive (HSV-1pos) sera or with sera that contained no anti-gC1 antibodies (HSV-2pos or HSVneg), and the residual viral infectivity was assayed in L (A), gro2C (B), sog9-EXT1 (C), HaCaT (D), and GMK AH1 (E) cells. The original virus-neutralizing titres of the three HSV-1 positive sera employed for purification of anti-gC1 antibodies were 160, 160, and 640 when assayed in GMK AH1 cells. The results are expressed as a percentage of the number of viral plaque forming units (PFU) obtained with antibody/serum-treated virus relative to mock-treated controls. truncated at aa 210 (C1-Δ210H and gGC1-ΔssΔ210) ( Table 2) suggesting that its epitope or part of it is located outside this region, or that B1C1 epitope is dependent on conformation of gC1. The latter possibility was supported by the pepscan analysis that failed to identify a linear epitope for this MAb (data not shown). However, binding of B1C1 to the site-altered mutants in gC, revealed lack of its reactivity with all mutant gC forms altered at arginines 143, 145, 147, 151 or 155, threonine 150, but not these altered at isoleucine 142 and phenylalanine 146 (Table 2) suggesting that specific arginine residues and threonine 150 are included in the B1C1 epitope. This observation was verified by the treatment of gC1 with p-hydroxyphenylglyoxal, an arginine blocking agent, which diminished the binding to gC1 of MAb B1C1 but not MAb C2H12 whose epitope, as reported above, did not contain arginines (data not shown). Given the fact that arginine residues at positions 143, 145, 147, 151 and 155, as well as isoleucine 142 and phenylalanine 146 are known to be important for binding of gC1 to HS/CS (Mardberg et al., 2001 (Mardberg et al., , 2002 , the B1C1 epitope seemed to selectively include specific aa residues from the attachment domain Table 2 Reactivity of anti-gC monoclonal antibodies with baculovirus-expressed gC fragments as well as mutant gC proteins altered at specific amino acid residues a . a The top eight constructs are specific fragments of gC1 expressed in baculovirus system (prepared in this work) while the remaining proteins are mutant gC1 carrying specific amino acid substitutions (Mardberg et al., 2001 (Mardberg et al., , 2002 Trybala et al., 1994) . In the schematic structure of the C1-full the numbering concerns aa positions of signal sequence (ss), cysteine residues (C), and terminal aa of the proteins. The positions of N-linked glycans are depicted with umbrellas. Presence of the His-tag is illustrated by linear sequence of six histidines (H). Solid boxes at the amino-terminal end in constructs gGC1-ΔssΔ302 and gGC1-ΔssΔ210 denote replacement of native ss of gC1 with ss derived from gG of pseudorabies virus. of gC1 (Mardberg et al., 2001; Tal-Singer et al., 1995; Trybala et al., 1994) thus being similar but not identical to this functional site.
We also tested whether human sera containing anti-gC1 antibodies could interfere with binding of B1C1 to purified gC1. The human sera collected from five of the six HSV-1 seropositive subjects, but not sera drawn from the two HSV-2 seropositive patients or from the three seronegative subjects inhibited the binding of B1C1 to gC1 (Fig. 5A ). It should be noted that the serum designated as HSV-1posA, which did not inhibit B1C1 binding, was almost devoid of anti-gC1 antibodies as judged from ELISA results (Table 1) . In contrast, the binding of MAb C2H12 to gC1 was only marginally inhibited by the human antibodies (Fig. 5B) . These results indicate that human HSV-1 immune sera contained antibodies targeting epitope(s) on gC1 similar to that of B1C1 MAb. Because the B1C1 epitope overlaps a part of the attachment domain of gC1 (see above), we conclude that the human B-cell response recognizes and strongly reacts with the region of gC1 responsible for the attachment of HSV-1 to cell surface HS/CS receptors.
Anti-gC antibodies protect mice from HSV-1 infection
To investigate whether anti-gC MAbs could protect mice from HSV-1 infection, the neurotropic 2762 strain of HSV-1 (Bergstrom et al., 1990) was pre-incubated for 30 min at 37°C with MAb B1C1, C2H12 or irrelevant mouse IgG1 MAb prior to intraperitoneal inoculation into BALBc mice. Each animal in groups of 10 received 5 µg of antibody and 100 or 500 PFU of the virus. In comparison with mice that received irrelevant control MAb, B1C1 but not C2H12 antibody extended survival of mice inoculated with either 100 or 500 PFU (Fig. 6) .
Preliminary experiment in which 5 mice received by the same route a mixture of human anti-gC1 antibodies (20 µg) and 100 PFU of HSV-1 2762 strain, revealed that while all 5 animals in control group died after 5 days of infection, all animals that received human anti-gC1 antibodies survived until the end of experiment at the day 20 (data not shown). Although these experiments were performed with the use of HSV-1 strain that was not employed in our cell culture assays, and a route of virus inoculation did not correspond to the known sites of primary HSV-1 infection of humans, the results indicate that murine B1C1 MAb or human anti-gC1 antibodies are capable of neutralizing HSV-1 infectivity in mice.
Discussion
Viral envelope glycoproteins are prominent targets for the host immune response and often utilized as antigens for serological assays and for immunization studies. HSV-1 gC is no exception to the rule, as it constitutes a major antigen for both the B-and T-cell responses. Although the antibodies to this protein develops relatively late during primary infection as compared to gB and gD, patients with recurrent herpetic lesions were reported to show increased IgG antibody reactivity to gC (Arvin et al., 1983) . Furthermore, gC was early found to 5 . The effect of gC1-antibody containing human sera on binding of murine MAbs to gC1. The HSV-1 positive sera with anti-gC1 antibody titers ranging from 100 to 3200 or human sera containing no detectable anti-gC1 antibodies (at titer of b100) were incubated at 37°C for 2 h with purified gC1 coated to plastic surface. Subsequently MAbs B1C1 (A) or C2H12 (B) were added and tested for binding to gC1. Shown in parentheses are values of anti-gC1 antibody titers. The results are expressed as a percentage of absorbance value obtained with MAb bound to serum-pre-treated gC1 relative to mock-treated controls. Two separate experiments were performed in duplicate for each antibody/serum sample. constitute a major T-cell antigen for the cytotoxic immune response . However, in contrast to reports on some animal herpesviruses showing that immunity to gC may control infection in vivo (Ober et al., 2000; Gupta et al., 2001) , the dispensability of HSV-1 gC for cell culture infection reported in some studies may have led to the erroneous assumption that gC antibodies are of less interest in comparison to the more widely studied indispensable glycoproteins as concerns induction of protective immunity to HSV-1. Here we show that in human HaCaT keratinocytes and in a cell culture model where gC plays a crucial role for attachment and infectivity, human antibodies to this protein are efficient inhibitors of viral infection. Furthermore the anti-gC MAb B1C1, which is known to be a potent inhibitor of HSV-1 attachment to cells (Svennerholm et al., 1991) and whose epitope is completely conserved among HSV-1 strains (Liljeqvist et al., 1999) , was found to be neutralizing in HaCaT keratinocytes, in cells exhibiting a restricted expression of GAGs, i.e. either HS or CS (sog9-EXT-1 and gro2C cells, respectively), or, in cells subjected to a modest endoglycosidic trimming of HS chains with heparinase III (GMK-AH1 cells). These results suggest that an ample expression of GAGs on surfaces of some cultured cells such as GMK AH1 prevents neutralization of HSV-1 infectivity by anti-gC1 antibodies. It has been reported that digestion of GMK AH1 (Trybala et al., 2000) or HEp-2 (Herold et al., 1994; Mardberg et al., 2001 ) cells with heparinase I rendered these cells less susceptible to infection with the gC1-deficient mutants than the wild-type HSV-1 implying that cleavage of HS chains reduces the binding sites for the gC-independent attachment of HSV-1 to cells. However in HEp-2 (Herold et al., 1994) or GMK AH1 (Adamiak, unpublished data) cells treated with heparinase III these differences were either absent or less pronounced. Heparinase I and III are known to target weakly and extensively sulfated stretches of HS chain respectively, however, identification of a domain structure of the non-digested cell-associated fragments of HS is difficult due to the lack of satisfactory methods of HS chain sequencing (Korir and Larive, 2009 ). Hence, as data on the CS and HS composition of mutant L cells, HaCaT and GMK AH1 cells are currently incomplete, we cannot yet define a common GAG denominator for this anti-gC1 antibody dependent neutralization, but we suggest that highly sulfated stretches of HS chain are required and maybe are better exposed after digestion of GMK AH1 cells with heparinase III. These results also suggest that the extent of gC-dependency in the binding of HSV-1 to cells (Herold et al., 1991; Griffiths et al., 1998; Tal-Singer et al., 1995; Trybala et al., 1994) , which was suggested to be the virus strain and the cell type dependent (reviewed by Spear, 2004) can be primarily affected by the abundant GAG expression on the surface of cultured cells or the presence of specific structures in GAG chains. Recognition of GAGs is known to offer a selective advantage for replication of some viruses in cultured cells (reviewed in Trybala et al., 2002) but not in their natural hosts most likely due to a less restricted expression of GAG molecules in in vitro growing cells. It is known that components of culture media may affect expression and fine structure of GAG chains (e.g. Brown et al., 1999; Morano et al., 1999) .
Mapping of the MAb by the use of baculovirus-expressed gC fragments showed that a shorter fragment encompassing a major GAG-binding domain was insufficient for binding of MAb B1C1, while a longer fragment including the carboxyterminal part of antigenic site II of gC (Wu et al., 1990) fulfilled both these two functions. Together with data from pepscan analysis that easily provided an epitope for the MAb C2H12 reactive with a continuous stretch of aa residues but failed to demonstrate a reactivity of the MAb B1C1 to any peptide, we conclude that a large portion of the N-terminal part of gC is necessary to achieve the proper conformation needed for B1C1 binding and that the epitope is overlapping but not identical with the GAG-binding domain of gC. Given a restricted system for study of HSV-1 attachment in form of gro2C cells or sog9 EXT-1 cells, gC antibodies purified from human sera did inhibit viral binding to the cell surface, albeit at low dilutions.
Most likely, this inhibition was caused by interference with viral binding to GAG molecules by gC. Thus we conclude that under conditions where gC function is necessary for viral binding, human antibodies can block this activity. Possibly, the anti-gC antibodies have a similar potency in vivo, considering the prominent B-cell response to this protein in infected individuals (Arvin et al., 1983) . When the question as to whether human anti-gC sera contain antibodies whose epitopes overlap that of B1C1 was investigated, almost all sera blocked binding of the MAb to gC. One cannot exclude that human anti-gC1 antibodies represent a set of polyclonal antibodies which recognize different domains of gC1 and some of these clones may outperform the activity of MAb B1C1. We interpret this finding as a strong indication that the human B-cell response targets the GAG-binding domain on gC, since the epitope of B1C1 shared several amino acid residues with this functional domain. It is of interest that this interaction, in addition to an effect in cell lines reduced in GAG expression, also influenced HSV-1 attachment to and infectivity of human keratinocytes, which are target cells for the natural infection of this virus. The importance of gC function for infection of human keratinocytes by another alphaherpesvirus, e.g. varicella-zoster virus (Moffat et al., 1998) underscores the need for further studies on the role of HSV-1 gC on early interactions with these cells.
Materials and methods
Cells and viruses
African green monkey kidney cells (GMK AH1) were propagated in Eagle's minimum essential medium (EMEM) supplemented with 2% newborn calf serum and 0.05% Primaton RT substance. Human skin keratinocyte (HaCaT) cells (Boukamp et al., 1988) were propagated in Dulbecco's modified EMEM (DMEM) supplemented with 10% fetal calf serum, 1% L-glutamine and antibiotics. These cells were used in experiments as monolayer cultures after 4-6 days of propagation. Murine L, gro2C, and sog9-EXT1 cells were kindly provided by Dr. Frank Tufaro, University of British Columbia, Vancouver. The gro2C cells (Gruenheid et al., 1993) were derived from L cells through selection pressure by lytic HSV infection, and appeared to be deficient in HS-but proficient in CS-expression on cell surfaces. Further selection pressure by HSV infection resulted in the HS/CS-deficient cell line sog9, and its HS-expression rescued variant sog9-EXT1 (McCormick et al., 1998) was used in the present study. These cells were grown in DMEM supplemented with 10% fetal calf serum. For culture of Sog9-EXT1 cells the medium was supplemented with geneticin to maintain cells with the transfected EXT1 gene. HSV-2 333 strain (Duff and Rapp, 1971) , HSV-1 KOS 321 strain (Holland et al., 1983) , the gC-negative derivative of KOS 321 designated gC − 39 (Holland et al., 1984) , and the HSV-1 mutants prepared by transfection of altered gC into gC − 39 (Mardberg et al., 2001) were used throughout the study.
Construction of baculovirus-expressed fragments of HSV-1 gC
The following fragments of HSV-1 gC were prepared (Table 2) . (i) Baculovirus-expressed complete gC (C1-full), was prepared by cloning the Nhe I (814)-Sph I (2571) 1758 bp fragment from the plasmid pGC (kindly provided by Dr. J. Glorioso, Pittsburgh School of Medicine, University of Pennsylvania) into the baculovirus transfer plasmid, pFastBac1 under the polyhedrin promoter. (ii) gC fragment without transmembrane and endodomain sequences (C1-TM − H) and gC fragment comprising amino acids 1-209 (C1-Δ210H) were constructed by PCR using pGC as a template with forward primer for both fragments 5′tagactagtctgccgggaacgctagccgatccctc3′ and reverse primers 5′ttttctgcagttaatgatgatgatgatgatgctcgatcgcctcgatca3′ (for C1-TM − H) and 5′ttttctgcagttaatgatgatgatgatgatgggccccctccgcccagag3′ (for C1-Δ210H). The forward primer was designed to contain the SpeI restriction site while the reverse primers were projected to additionally add six histidine residues at 3′ end followed by stop codon and by the sequence recognized by PstI restrictase. The SpeI-PstI 1503 and 703 bp fragments were ligated into linearized transfer vector. (iii) Constructs carrying internal in-frame deletions of regions coding for mucin-like region (amino acids 33-123) or another part of gC ectodomain (amino acids 360-453) were prepared by digestion of C1-TM − H fragment with XbaI followed by filling in the protruding ends with Klenow fragment polymerase, cleavage with NruI and re-ligation (C1-Δ360H) or by digestion of the same template with ApaI and religation (C1-ΔmucTM − H) (Tal-Singer et al., 1995) . Both these procedures were combined to prepare construct with both these deletions (C1-ΔmucΔ360H). (iv) The gC fragment comprising amino acids 65-301 (gGC1-ΔssΔ302) was prepared by digestion of pGC with TaqI at nucleotides 1039 and 1753, cloning into pFastBacssgG plasmid (obtained by fusion of pFastBac1 with the PRV gG signal sequence).
(v) The gC fragment comprising amino acids 82-209 (gGC1-ΔssΔ210) was prepared by digestion of pGC with NaeI at nucleotides 1090 and 1475 and cloning into pFastBacssgG. All recombinant transfer vectors were analysed by digestion with endonucleases and were used to generate recombinant baculoviruses according to manufacturer's protocol (Bac-to-Bac Expression System; Life Technologies). Baculovirusexpressed fragments of gC comprising His-tag were purified by Ni-NTAaffinity chromatography while all other fragments by immunoaffinity chromatography using MAb B1C1 or C2H12.
Site-directed mutagenesis of HSV-1 gC
The assay was performed by using Promegas Altered Sites II in vitro Mutagenesis System (Scandinavian Diagnostic Services, Falkenberg, Sweden) as described previously (Mardberg et al., 2001) . Briefly, the pAltgC plasmid that contained an insert of 639 bp of HSV-1 gC DNA was used as a template for site-specific alterations. Mutagenesis primers (Scandinavian Gene Synthesis, Koping, Sweden) were designed to convert positively charged and hydrophobic amino acids in the N-terminal part of gC to alanines and threonines, respectively. Template with confirmed alterations was subcloned into plasmid pGC and then co-transfected with gC − 39 (a gC-null mutant) genomic DNA into vero cells. Mutant viruses with recombined gC protein were identified and purified to homogeneity by using an immunoreactive black plaque assay. The list of mutated variants is shown in Table 2 .
Purification of virus particles and viral envelope glycoprotein gC
Methyl 3 H-thymidine labelled virions were purified from infectious culture media of GMK AH1 cells by centrifugation through a three-step discontinuous sucrose gradient (Karger and Mettenleiter, 1993) . Relative amounts of virions in preparations of purified virus were evaluated by comparing DNA contents (Karger et al., 1995) . The viral gC was purified by immunoaffinity chromatography as described previously (Trybala et al., 2000) using the MAb B1C1 (Olofsson et al., 1999) . To minimize the amount of detergent in purified viral proteins, the columns were washed with detergent-free washing buffer just prior to the elution of the protein.
Anti-gC antibodies and their reactivity
Sera, listed in Table 1 , were collected from six patients suffering from oral herpetic lesions that were isolation-positive for HSV-1. Sera from two patients infected with HSV-2 only and sera from three seronegative subjects were used as controls. Presence of antibodies specific for HSV and specific HSV glycoproteins was tested by an ELISA-based method. Antibodies specific for HSV-1 gC were isolated from human sera by the gC-affinity chromatography according to the procedure described earlier for HSV-2 gG (Liljeqvist et al., 1998) , using purified gC as sorbent.
The anti-gC MAbs used were B1C1 MAb previously suggested to recognize a discontinuous type-specific epitope overlapping the major GAG-binding domain at the N-terminal part of gC (Trybala et al., 1994; Olofsson et al., 1999; Mardberg et al., 2001) , and the type-common MAb C2H12 (Bergstrom et al., 1992; Sjoblom et al., 1992) which is reactive in immunoblotting and therefore most likely recognizes a linear epitope. Verification of the presence of arginine residue in a MAb epitope was carried out as described by Yamasaki et al. (1980) . Briefly, purified gC, pre-adsorbed to the plastic surface, was treated with specific concentrations of p-hydroxyphenylglyoxal, a substance which chemically modifies the guanidyl group of the arginine residue (Yamasaki et al., 1980) . After washing, residual reactivity of gC with MAbs was tested by an ELISA-based method.
Pepscan analysis of anti-gC MAbs and purified human anti-gC antibodies
The anti-gC MAbs B1C1 and C2H12 were tested for their binding to a panel of overlapping peptides prepared on a continuous cellulose support (13-mers with 11 amino acids overlaps), (Jerini Bio Tools) according to a standard spot synthesis protocol (Frank, 1992; Kramer et al., 1994) . The peptides covered the aa 121 to 300 of the gC protein and the sequences were deduced from nucleotide sequence data derived from strain KOS 321. The cysteine residues were replaced by serines to avoid oxidation during the incubation steps. The membrane was washed in methanol and three times in Tris-buffered saline (TBS) containing 0.05% Tween-20, pH 8.0 (T-TBS) and incubated overnight with blocking buffer (Genosys Biotechnologies) diluted 1:10 in T-TBS supplemented with 50 mg/ml of sucrose. The respective MAb, diluted in blocking buffer to a concentration of 1 µg/ml was added and incubated with a membrane for 3 h at room temperature. After triple washing, peroxidase-conjugated rabbit anti-mouse IgG (Dako) was added in blocking buffer at a concentration of 1 µg/ml and incubated for 2 h. The membrane was developed with ECL-detection solution on X-Omat S film.
HSV attachment-inhibition assay
Monolayer cultures of cells growing in 96-well cluster plates were precooled to 4°C. The cells were washed with PBS (137 mM NaCl, 2.7 mM KCl, 8.1 mM Na 2 HPO 4 , 1.5 mM KH 2 PO 4 ) supplemented with 1 mM CaCl 2 and 0.5 mM MgCl 2 (PBS-A) and blocked for 1 h with PBS-A containing 1% bovine serum albumin. Radiolabeled viral particles were mixed with specific concentrations (0-56 μg/ml) of anti-gC MAb and incubated at 4°C for 30 min. Thereafter, the mixtures were added to cells and virus adsorption was allowed for 1 h at 4°C. Subsequently the cells were washed three times with PBS-A, lysed with 0.2 ml of PBS containing 5% SDS, and finally transferred to scintillation vials for quantification of radioactivity.
HSV-1 plaque-reduction assays
Effect of human sera, purified human anti-gC IgG antibodies, and murine anti-gC MAbs on HSV infectivity was tested as follows. Confluent monolayers of 2-3 days old cells in 6 well plates were washed twice with 2 ml of Dulbecco's modified Eagle medium. Two ml portions of the same medium containing 0.2 % of HSV-negative human serum as well as indicated dilutions of the test sera (inactivated at 56°C for 30 min) or purified antibodies were pre-incubated with approximately 200 plaque forming units (PFU)/ml of the virus (KOS 321) for 30 min at 37°C. One ml portions of the mixture were added per well and left for adsorption for a further 1 h min at 37°C. The cells were then washed twice with 2 ml of the medium and overlaid with 3 ml of 1% methylcellulose solution in the same medium. After incubation for 4-5 days at 37°C the cells were stained with 1% solution of crystal violet to visualise the viral plaques.
HSV-1 plaque-reduction assay with anti-gC MAbs and the GAGdegrading enzyme pre-treated GMK AH1 cells was carried out as follows. Confluent monolayers of 3 day old GMK AH1 cells in 12 well plates were washed twice with 1 ml of Eagle's medium, and 0.5 ml portions of the same medium containing 0.2% BSA and 1 U/ml of heparinase I (Sigma) or heparinase III (Sigma) or chondroitinase ABC (Sigma) or the mixture of all of these enzymes was added to the cells. The cells were left for the digestion at 37°C for 1 h. One ml portions of Eagle's medium containing 0.2% of HSV-negative human serum as well as 20 µg/ml of anti-gC-1 MAb were pre-incubated with approximately 200 PFU of KOS 321 for 45 min at 37°C, and 0.5 ml portions of the virus-MAb mixture were added to cells and left for adsorption for a further 30 min at 37°C. The rest of the procedure was as described above.
Effect of purified human anti-gC antibodies on binding of B1C1 MAb to gC
A MAb-inhibition assay using human sera was performed as described previously (Ross et al., 1985) . Purified gC was coated onto 96-well plates (Maxisorp) in carbonate buffer, pH 9.6. Subsequently, serial tenfold dilutions of human sera showing reactivity to HSV-1 or HSV-2, or being seronegative to HSV (see Table 1 for characterization) were added to pre-adsorbed gC and incubated at 37°C for 2 h. MAbs B1C1 or C2H12 were added to the same wells to obtain a final concentration of 70 and 20 ng/ml, respectively. Following overnight incubation of the mixtures at 37°C, the plates were rinsed and alkaline phosphatase-conjugated goat anti-mouse antibodies (Jackson) were added. Following addition of the substrate, absorbance values were read at 405 nm.
HSV-1 infection of mice in the presence of anti-gC MAbs
HSV-1 strain 2762 (Bergstrom et al., 1990) at fivefold dilutions in Hanks medium was mixed with MAb B1C1, C2H12 or irrelevant mouse IgG1 (namely V-38 3C4B4E2) antibody (all at 10 µg/ml) and incubated at 37°C for 30 min. All mixtures were supplemented with 0.2% mouse HSV-negative serum for protection of virus infectivity during the incubation. Approximately 0.5 ml of this mixture containing 5 µg of antibody and 100 or 500 viral PFU was inoculated intraperitoneally into 4-6 week old BALBc mice. The mice were observed daily for 14 days for the presence of the virus-induced symptoms.
